Product Images Anagrelide

The text presents the mean platelet count of patients with thrombocytosis secondary to myeloproliferative disorder during anagrelide therapy. The mean platelet count is measured in x10^L and ranged from 1200g to 207 during the 208 weeks of treatment. The number of subjects for each time point is also shown.*

Anagrelide Capsules, USP, are a medication used as a platelet-reducing agent. Each capsule contains 0.5 mg of anagrelide base (as anagrelide hydrochloride, USP), and the recommended starting dosage is 0.5 mg 4 times a day or 1 mg twice a day, which can be adjusted if needed. The total daily dose should not exceed 10 mg. It is essential to keep the drug out of reach of children and store it at 20° to 25°C (68° to 77°F) in a light-resistant container with a child-resistant closure. The medication is manufactured by Torrent Pharmaceuticals Ltd., India, and is available in a pack of 30 capsules. The full details can be found in the package insert.*

Biac capsules are a platelet-reducing agent manufactured by Torrent Pharmaceuticals. The capsules contain 1 mg of Anagrelide base and the recommended starting dosage should be maintained for at least one week, but dosage may require adjustment. The drug should be kept out of the reach of children and stored in a cool and dry place. Biac capsules should be dispensed in a light-resistant container with a child-resistant closure. Complete information on the dosage and administration of the drug can be found in a separate insert.*